Type II Diabetes Mellitus Clinical Trial
Official title:
Using Technology to Share Fitness Goals and Results to Improve Diabetes Outcomes
The investigators will recruit DoD beneficiaries, aged 18 years or older and diagnosed as being Type II diabetic. Patients will be randomized into one of two groups. Group 1 will use a fitness tracker but will not be able to see other participants data and group 2 will use a fitness tracker and will be able to see other members daily and weekly results. Outcome measures will be assessed at baseline, 3 months and 6 months to include hemoglobin A1c, weight, body mass index, blood pressure, and number of hours and days fitness tracker is used. The goal is to see if the group randomized into an online community will have improved activity and outcome measurements compared with those who use the pedometer alone.
Male and female DoD beneficiaries ages 18 years or older who have been diagnosed with Type II
diabetes, will be recruited at the Mike O'Callaghan Federal Medical Center (MOFMC).
Screening Visit:
- Obtain signed Informed Consent Document and HIPAA Authorization (research-driven).
- Record: Date of birth, phone number, age, gender, race, ethnicity, social security
number, current email address, height (in inches), weight (in pounds), blood pressure,
medications list including any over-the-counter and prescription weight loss medication
(name, strength, dose) or supplements.
- Subjects will have the following standard of care blood test drawn which include:
- Hemoglobin A1c via 1 venipuncture (5-10 mls, approximately 1-2 teaspoons of blood
will be drawn)
Visit 1 (Day 1 within 1 week of Screening Visit):
- Record: Weight (in pounds), blood pressure, and any changes to their medications list.
- Subjects will complete the RAND 36 Item Health Survey.
- Subjects will complete the Intake Questionnaire.
- Subjects will be assigned their Fitness Tracker username and their username and password
will be recorded by the Research Coordinator.
- Subjects will be given User Instructions based off of their randomization group.
- Subjects will be instructed to follow all research procedures and that failure to do so
may result in the removal from the study and the return of the Fitness Tracker.
- Subjects will be randomized by the research coordinator using a random-number generator
into one of two groups (research-driven):
- Group 1: will use a fitness tracker but will not be able to see other participant's
data.
- Group 2: will use a fitness tracker and will be able to see other member's daily
and weekly results.
- Both groups will receive the scripted feedback at set time intervals by the
Research Coordinators.
- Subjects will be provided a fitness tracker and instructed on how to use it.
- If subject is a DoD beneficiary, and finishes all study-related procedures at month
6, they will keep the fitness tracker. If a subject does not complete all
study-related procedures, they will be asked to return the fitness tracker so the
investigators can erase their data and re-issue to another study subject.
- If subject is active duty or a DoD employee, regardless of their study completion,
they will be asked to complete Temporary Issue Receipt and bring back the fitness
tracker at the end of the study.
Visit 2 (Month 3/90 days post Visit 1):
- Record: Weight (in pounds), blood pressure and any changes to their medications list.
- Subjects will complete the RAND 36 Item Health Survey.
- Subjects will complete the Follow up Questionnaire.
- Obtain information from their fitness tracker.
- Subjects will have the following standard of care blood test drawn which include:
- Hemoglobin A1c via 1 venipuncture (5-10 mls, approximately 1-2 teaspoons of blood
will be drawn)
Final Visit 3 (Month 6/90 days post Visit 2):
- Record: Weight (in pounds), blood pressure and any changes to their medications list.
- Subjects will complete the RAND 36 Item Health Survey and be asked some additional
questions.
- Subjects will complete the Follow up Questionnaire.
- Obtain information from their fitness tracker.
- Subjects will have the following standard of care blood test drawn which include:
- Hemoglobin A1c via 1 venipuncture (5-10 mls, approximately 1-2 teaspoons of blood
will be drawn)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01952535 -
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01196728 -
Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes
|
Phase 1 | |
Terminated |
NCT00997152 -
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
|
Phase 2 | |
Completed |
NCT02592421 -
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
|
Phase 3 | |
Completed |
NCT05544214 -
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01969084 -
The Effect of Linagliptin on Mitochondrial and Endothelial Function
|
Phase 4 | |
Terminated |
NCT01644201 -
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
|
Phase 3 | |
Completed |
NCT00995787 -
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
|
Phase 1 | |
Completed |
NCT01020123 -
Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients
|
Phase 2 | |
Completed |
NCT01505426 -
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients
|
Phase 3 | |
Completed |
NCT01262586 -
Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.
|
Phase 3 | |
Completed |
NCT00561171 -
Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria
|
Phase 2 | |
Active, not recruiting |
NCT03912363 -
Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids
|
N/A | |
Completed |
NCT01868646 -
Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus
|
Phase 4 | |
Active, not recruiting |
NCT06386328 -
A Clinical Trial to Evaluate the Food Effect of CKD-378
|
Phase 1 | |
Terminated |
NCT02749435 -
A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus
|
N/A | |
Completed |
NCT00894868 -
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
|
Phase 4 | |
Recruiting |
NCT01165190 -
Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans
|
N/A | |
Completed |
NCT01255085 -
Yellow Pea Protein and Fibre and Short Term Food Intake
|
N/A | |
Completed |
NCT02156349 -
A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.
|
N/A |